AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Oct 30, 2024
32883_dirs_2024-10-30_d702d561-fbc3-4529-9179-3a86322f4d77.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-10-28
Reporting Person: Radhakrishnan Karthik (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-10-28 | Common Stock | P | 1550 | $16.25 | Acquired | 1550 | Direct |
Footnotes
F1: The price reported in Column 4 is the Public offering price in the prospectus dated October 28, 2024.